Robert H. Andtbacka
Experienced in Angiosarcoma

Dr. Robert H. Andtbacka

General Surgery | Surgical Oncology
50 N Medical Dr, 
Salt Lake City, UT 
Experienced in Angiosarcoma
50 N Medical Dr, 
Salt Lake City, UT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Robert Andtbacka is a General Surgeon and a Surgical Oncologist in Salt Lake City, Utah. Dr. Andtbacka is rated as an Experienced provider by MediFind in the treatment of Angiosarcoma. His top areas of expertise are Melanoma, Adult Soft Tissue Sarcoma, Liposarcoma, and Retroperitoneal Liposarcoma.

His clinical research consists of co-authoring 68 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
General Surgery
Surgical Oncology
Licenses
Surgery in UT
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

50 N Medical Dr, Salt Lake City, UT 84132

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

An Observational Pilot Study to Compare the Compliance With and Health Related Quality of Life During Therapy With Standard High-Dose Interferon Alfa (Intron A, HDI) Versus Pegylated Alfa-Interferon 2b (Sylatron, PEG IFN) in Patients With Surgically Resected Melanoma
An Observational Pilot Study to Compare the Compliance With and Health Related Quality of Life During Therapy With Standard High-Dose Interferon Alfa (Intron A, HDI) Versus Pegylated Alfa-Interferon 2b (Sylatron, PEG IFN) in Patients With Surgically Resected Melanoma
Enrollment Status: Completed
Publish Date: February 13, 2025
A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC and Embedded Phase I/IIa Trial With Tumor Lysate Particle Only (TLPO) Vaccine in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.
A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC and Embedded Phase I/IIa Trial With Tumor Lysate Particle Only (TLPO) Vaccine in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drug: Tumor Lysate, Particle-Loaded, Dendritic Cell Vaccine
Study Phase: Phase 2
A Multicenter Phase 2, Open Label Study of Intratumoral Tavokinogene Telseplasmid (Tavo, pIL-12) + Electroporation With Pembrolizumab in Patients With Stage 3/4 Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment
A Multicenter Phase 2, Open Label Study of Intratumoral Tavokinogene Telseplasmid (Tavo, pIL-12) + Electroporation With Pembrolizumab in Patients With Stage 3/4 Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment
Enrollment Status: Unknown
Publish Date: March 27, 2023
Intervention Type: Biological, Device
Study Drugs: Tavokinogene Telseplasmid, Pembrolizumab
Study Phase: Phase 2
A PHASE 1b STUDY OF INTRATUMORAL CAVATAK® (COXSACKIEVIRUS A21, CVA21) AND IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA (VLA-013 MITCI)
A PHASE 1b STUDY OF INTRATUMORAL CAVATAK® (COXSACKIEVIRUS A21, CVA21) AND IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA (VLA-013 MITCI)
Enrollment Status: Completed
Publish Date: January 17, 2023
Intervention Type: Biological, Drug
Study Phase: Phase 1
Phase II Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma (Neo-NivoHF10)
Phase II Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma (Neo-NivoHF10)
Enrollment Status: Terminated
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 2
PV-10 Intralesional Injection vs Systemic Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
PV-10 Intralesional Injection vs Systemic Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
Enrollment Status: Terminated
Publish Date: January 19, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors or Lymphomas
A Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Enrollment Status: Terminated
Publish Date: December 30, 2021
Intervention Type: Biological, Drug
Study Phase: Phase 1
An Open-label, Phase II, Multicenter Study of Enhancing Pembrolizumab Responses in Melanoma Through Intratumoral pIL-12 Electroporation
An Open-label, Phase II, Multicenter Study of Enhancing Pembrolizumab Responses in Melanoma Through Intratumoral pIL-12 Electroporation
Enrollment Status: Completed
Publish Date: January 06, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

68 Total Publications

Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease.
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease.
Journal: Journal for immunotherapy of cancer
Published: February 22, 2024
Similar Doctors
Distinguished in Angiosarcoma
Dr. Cara M. Guilfoyle
General Surgery
Distinguished in Angiosarcoma
Dr. Cara M. Guilfoyle
General Surgery

Catholic Health Initiatives Colorado

3000 N Triumph Blvd, Suite 110, 
Lehi, UT 
 (24.0 miles away)
385-345-3555
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Cara Guilfoyle is a General Surgeon in Lehi, Utah. Dr. Guilfoyle is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. Her top areas of expertise are Breast Cancer, Angiosarcoma, Inflammatory Breast Cancer, Lymphadenectomy, and Mastectomy. Dr. Guilfoyle is currently accepting new patients.

Distinguished in Angiosarcoma
Dr. Marla W. Dudak
Surgical Oncology | General Surgery
Distinguished in Angiosarcoma
Dr. Marla W. Dudak
Surgical Oncology | General Surgery
Salt Lake City, UT 
 (6.6 miles away)
801-948-2380
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Marla Dudak is a Surgical Oncologist and a General Surgeon in Salt Lake City, Utah. Dr. Dudak is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Intraductal Papilloma, Inflammatory Breast Cancer, and Lymphadenectomy. Dr. Dudak is currently accepting new patients.

Distinguished in Angiosarcoma
Dr. Jennifer J. Tittensor
General Surgery
Distinguished in Angiosarcoma
Dr. Jennifer J. Tittensor
General Surgery

Utah Surgical Associates Inc

3550 N University Ave, Suite 250, 
Provo, UT 
 (35.2 miles away)
801-374-9625
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Jennifer Tittensor is a General Surgeon in Provo, Utah. Dr. Tittensor is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, Lymphadenectomy, and Mastectomy. Dr. Tittensor is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Andtbacka's expertise for a condition
ConditionClose
    View All 20 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile